Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01874626 · ClinicalTrials.gov registry record · Phase 3

Efficacy and Safety of SST 0225, a Topical Ibuprofen Cream, in the Treatment of Pain Associated With Acute Ankle Sprain

A Phase 3 study, sponsored by Strategic Science & Technologies.

Completed
Registry status
Phase 3
Development phase
305
Enrollment target

NCT01874626 is a Phase 3 study that has completed, run by Strategic Science & Technologies. The registered enrollment target is 305 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01874626, a Phase 3 study, has completed, sponsored by Strategic Science & Technologies.

COMPLETED
Registry status
Phase 3
Development phase
305 participants
Enrollment target

Study Summary

This is a randomized, multi-center, double-blind, placebo-controlled, multi-dose, parallel-group study. Approximately 300 subjects (150 per group) 16 years of age and older with a current (within 24 hours from Visit 1) Grade I or II ankle sprain, and who meet all eligibility criteria, will be randomized into the study and will receive either the active treatment (SST-0225 ibuprofen cream), or matching placebo. Subjects will apply an amount equivalent to a 4 inch line of investigational product to the affected ankle approximately every 4-6 hours. At Visit 1 two doses will be applied at the site. All subsequent doses of the investigational product will be applied every 4 to 6 hours with a total of 4 doses in a 24 hour period. Duration of treatment with the investigational product is 7 days.

Interventions

  • DRUG Placebo
  • DRUG SST-0225 Topical Ibuprofen Cream

Trial Details

FieldValue
Enrollment Target 305 participants
Start Date 2013-06
Est. Completion 2014-01
Phase Phase 3

Sponsor

Strategic Science & Technologies

8 total trials

What the Registry Record Tells You About NCT01874626

The ClinicalTrials.gov registry entry for NCT01874626 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 305 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Strategic Science & Technologies, which has 8 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT01874626 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01874626 about?

NCT01874626 is a clinical study titled "Efficacy and Safety of SST 0225, a Topical Ibuprofen Cream, in the Treatment of Pain Associated With Acute Ankle Sprain". This is a randomized, multi-center, double-blind, placebo-controlled, multi-dose, parallel-group study. Approximately 300 subjects (150 per group) 16 years of age and older with a current (within 24 hours from Visit 1) Grade I or II ankle sprain, and who meet all eligibility criteria, will be random...

What is the current status of trial NCT01874626?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 305 participants. The study started on 2013-06. Estimated completion is 2014-01.

What interventions are being tested in trial NCT01874626?

The interventions under investigation include: Placebo (DRUG), SST-0225 Topical Ibuprofen Cream (DRUG).

Who is sponsoring clinical trial NCT01874626?

This trial is sponsored by Strategic Science & Technologies, which has 8 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.